Phase 2 trial of standard neoadjuvant chemotherapy or patritumab deruxtecan (U3-1402; HER3-DXd) with or without endocrine therapy for high-risk HR+/HER2- breast cancer: VALENTINE Trial.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: SOLTI
- Phase: II
- Execution start: 29/11/2022
- End of execution: 30/10/2029
- IP: ENCARNA GONZALEZ FLORES